A bonanza of cardiology news!
Novartis’ new HPB drug, Tekturna, shows solid results used with Diovan.
Angiomax from The Medicines Company is effective in anti-clotting trial (anti-clotting is big news these days…)
Schering-Plough has promising results for its investigational blood thinner.
New heart failure drug: symptom relief, but no extended life (a single, but everyone still looking for the home run).
Curious result for potent Lilly experimental cholesterol drug – ho-hum efficacy.
Will antisense drugs finally break through? Maybe.
Stents, stents, and more stents! Abbott’s new experimental stent looks like a real winner – too bad it has such a non-intuitive name (Xience). Abbott also looks to score with the first absorbable (dissolving) stent. But here’s an interesting study result – angioplasty no more effective than drug therapy? That’s a potential clinical practice game-changer.
Pfizer appears to be losing out on some Norvasc patent life. This not only has positive ramifications for makers of generics, but also for Novartis, who has a combo drug using amlopidine teed up.
Speaking of combos, Merck is already moving forward with a Januvia/metformin combo for diabetes. This article with commentary from Pharmalot, one my top daily sources for pharma news.
Accomplia, Sanofi’s new weight loss drug, seems to be on an approval treadmill. This article from the new Wall Street Journal Health blog, a new entry into the pharma blogosphere that is quite high-quality.
Leave a Reply